---
title: Pacira BioSciences Executive Kristen Williams Has Sold $14M in PCRX Stock — Annual Pattern Continues
type: news
slug: pacira-biosciences-williams-14-million-career-insider-sales-pharma-2026
canonical_url: https://13finsight.com/news/pacira-biosciences-williams-14-million-career-insider-sales-pharma-2026
published_at: 2026-03-02T01:27:19.168Z
updated_at: 2026-03-02T01:27:30.026Z
author: Alex Rivera
author_title: Breaking News Editor
author_url: https://13finsight.com/authors/alex-rivera
word_count: 217
locale: en
source: 13F Insight
---

# Pacira BioSciences Executive Kristen Williams Has Sold $14M in PCRX Stock — Annual Pattern Continues

> Kristen Williams, a Pacira BioSciences executive, has sold $14M in PCRX stock over 141 transactions in a consistent annual selling pattern since 2019.

Kristen Williams, an executive at Pacira BioSciences (PCRX), has sold $14 million in company stock across 141 transactions in a remarkably consistent annual pattern. The Numbers MetricValue Career Sell Value$14.0M Career Buy Value$0 Total Transactions141 Last Transaction2026-02-02 Shares Remaining131,303 Recent Activity DateTypeSharesPriceEst. Value 2026-02-02Sell13,137$20.5300$270K 2025-06-04Sell14,376$26.2400$377K 2024-06-13Sell7,452$28.3800$211K 2023-06-14Sell6,467$37.0300$239K 2023-06-07Sell1,357$37.8650$51K Williams sold 13,137 shares at $20.53 on February 2, 2026, for approximately $270K. Her pattern shows annual selling clusters — June 2025 ($377K), June 2024 ($211K), June 2023 ($290K), June 2022 ($521K) — suggesting a recurring 10b5-1 plan execution window. What It Means Williams' selling follows a textbook 10b5-1 pattern: clustered disposals once or twice per year, typically around the same calendar months. The declining per-trade values — from $521K in 2022 to $270K in 2026 — mirror PCRX's share price erosion from $60+ to $20, not changes in her selling behavior. For PCRX investors, Williams' 131,303 remaining shares represent meaningful continued exposure. Pacira's non-opioid pain management portfolio faces both opportunity and competition as the healthcare industry navigates post-opioid-crisis treatment paradigms. The consistent selling without acceleration at declining prices is modestly constructive. What to Watch PCRX share price trajectory and pain management market share Whether Williams adjusts her selling plan at $20 price levels FDA updates on Pacira's Exparel and iovera portfolios Other PCRX insider activity for corroborating signals

---

Source: 13F Insight — https://13finsight.com/news/pacira-biosciences-williams-14-million-career-insider-sales-pharma-2026
Author: Alex Rivera — https://13finsight.com/authors/alex-rivera
Last updated: 2026-03-02T01:27:30.026Z